Kobayashi Pharmaceutical

Kobayashi Pharmaceutical, the Japanese company at the center of a supplement contamination scandal linked to suspected deaths, is reportedly considering a buyout offer valued at more than ¥500 billion. The move would mark a major development for a firm whose reputation and finances have been damaged since the scandal, and is drawing attention from investors and observers of Japan's consumer health sector.